REFRENCES
Chihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto,
T., Ogawa, M., Toda, T., & Yamamura, T. (2011). Interleukin 6 signaling
promotes anti-aquaporin 4 autoantibody production from plasmablasts in
neuromyelitis optica. Proceedings of the National Academy of Sciences,
108(9), 3701–3706. https://doi.org/10.1073/pnas.1017385108
Correa-Díaz, E. P., Torres-Herrán, G. E., Miño Zambrano, J. E.,
Paredes-Gonzalez, V., & Caiza-Zambrano, F. J. (2021). Impact of
Rituximab on relapse rate and disability in an Ecuadorian cohort of
patients with neuromyelitis optica spectrum disorders. Multiple
Sclerosis and Related Disorders, 48, 102683.
https://doi.org/10.1016/j.msard.2020.102683
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock,
S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R.,
Marignier, R., Green, A. J., Aktas, O., Hartung, H. P., Lublin, F. D.,
Drappa, J., Barron, G., Madani, S., Ratchford, J. N., She, D., . . .
Katz, E. (2019). Inebilizumab for the treatment of neuromyelitis optica
spectrum disorder (N-MOmentum): a double-blind, randomised
placebo-controlled phase 2/3 trial. The Lancet, 394(10206), 1352–1363.
https://doi.org/10.1016/s0140-6736(19)31817-3
Cree, B. A., & Wingerchuk, D. M. (2005). Acute transverse myelitis: Is
the “idiopathic” form vanishing? Neurology, 65(12), 1857–1858.
https://doi.org/10.1212/01.wnl.0000194615.51750.f8
Ip, V. H., Lau, A. Y., Au, L. W., Fan, F. S., Chan, A. Y., Mok, V. C.,
& Wong, K. S. L. (2013). Rituximab reduces attacks in Chinese patients
with neuromyelitis optica spectrum disorders. Journal of the
Neurological Sciences, 324(1–2), 38–39.
https://doi.org/10.1016/j.jns.2012.09.024
Jacob, C. M. A., Pastorino, A. C., Fahl, K., Carneiro-Sampaio, M., &
Monteiro, R. C. (2008). Autoimmunity in IgA Deficiency: Revisiting the
Role of IgA as a Silent Housekeeper. Journal of Clinical Immunology,
28(S1), 56–61. https://doi.org/10.1007/s10875-007-9163-2
Jarius, S., & Wildemann, B. (2010). AQP4 antibodies in neuromyelitis
optica: diagnostic and pathogenetic relevance. Nature Reviews Neurology,
6(7), 383–392. https://doi.org/10.1038/nrneurol.2010.72
Kim, S. H., Huh, S. Y., Lee, S. J., Joung, A., & Kim, H. J. (2013). A
5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis
Optica Spectrum Disorder. JAMA Neurology, 70(9), 1110.
https://doi.org/10.1001/jamaneurol.2013.3071
Yan, L., Kimko, H., Wang B., Cimbora, D., Katz, E., & Rees, W. A.
(2021) Population pharmacokinetic modeling of inebilizumab in subjects
with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis or
relapsing Multiple Sclerosis. Clin Pharmacokinet, (submitted)
The trials mention in the manuscript are registered with
www.clintrials.gov.